company background image
ABCL

AbCellera Biologics NasdaqGS:ABCL Stock Report

Last Price

US$10.11

Market Cap

US$2.9b

7D

-1.7%

1Y

-54.0%

Updated

29 Jun, 2022

Data

Company Financials +
ABCL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

ABCL Stock Overview

AbCellera Biologics Inc. develops antibody discovery platform.

AbCellera Biologics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AbCellera Biologics
Historical stock prices
Current Share PriceUS$10.11
52 Week HighUS$22.63
52 Week LowUS$5.42
Beta0
1 Month Change27.98%
3 Month Change3.69%
1 Year Change-54.05%
3 Year Changen/a
5 Year Changen/a
Change since IPO-82.84%

Recent News & Updates

Jun 06

AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying

AbCellera stock has continued to struggle of late given the absolutely terrible sentiment in the biotech market, however the company's actual business is thriving under the surface. In the Q1 earnings call, the company highlighted both the internally developed T-Cell engager platform, along with the Empirico deal which provides the option to co-invest in programs. The company is currently sitting on a mountain of cash, $786 million worth and this balance looks to grow further with $334 million in accrued receivables from bebtelovimab. Insiders clearly appreciate the opportunity ahead as the CEO, CFO & COO each purchased significant amounts of stock directly after the Q1 release and insiders now own over 27% of the business.

May 13
Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

AbCellera Biologics Inc. ( NASDAQ:ABCL ) shareholders will have a reason to smile today, with the analysts making...

Shareholder Returns

ABCLUS Life SciencesUS Market
7D-1.7%3.7%1.6%
1Y-54.0%-18.0%-20.8%

Return vs Industry: ABCL underperformed the US Life Sciences industry which returned -19% over the past year.

Return vs Market: ABCL underperformed the US Market which returned -20.4% over the past year.

Price Volatility

Is ABCL's price volatile compared to industry and market?
ABCL volatility
ABCL Average Weekly Movement11.3%
Life Sciences Industry Average Movement11.4%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: ABCL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: ABCL's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012400Carl Hansenhttps://www.abcellera.com

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners.

AbCellera Biologics Fundamentals Summary

How do AbCellera Biologics's earnings and revenue compare to its market cap?
ABCL fundamental statistics
Market CapUS$2.88b
Earnings (TTM)US$204.82m
Revenue (TTM)US$489.04m

14.0x

P/E Ratio

5.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ABCL income statement (TTM)
RevenueUS$489.04m
Cost of RevenueUS$146.22m
Gross ProfitUS$342.82m
Other ExpensesUS$138.01m
EarningsUS$204.82m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.72
Gross Margin70.10%
Net Profit Margin41.88%
Debt/Equity Ratio0%

How did ABCL perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ABCL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ABCL?

Other financial metrics that can be useful for relative valuation.

ABCL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.4x
Enterprise Value/EBITDA7.4x
PEG Ratio-0.3x

Price to Earnings Ratio vs Peers

How does ABCL's PE Ratio compare to its peers?

ABCL PE Ratio vs Peers
The above table shows the PE ratio for ABCL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average28.6x
STVN Stevanato Group
32x11.0%US$4.2b
MEDP Medpace Holdings
24.1x13.4%US$4.8b
SHC Sotera Health
42x25.9%US$5.7b
MRVI Maravai LifeSciences Holdings
16.2x2.3%US$7.1b
ABCL AbCellera Biologics
14x-52.3%US$2.9b

Price-To-Earnings vs Peers: ABCL is good value based on its Price-To-Earnings Ratio (14x) compared to the peer average (28.6x).


Price to Earnings Ratio vs Industry

How does ABCL's PE Ratio compare vs other companies in the US Life Sciences Industry?

Price-To-Earnings vs Industry: ABCL is good value based on its Price-To-Earnings Ratio (14x) compared to the US Life Sciences industry average (30.3x)


Price to Earnings Ratio vs Fair Ratio

What is ABCL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ABCL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14x
Fair PE Ratio11.8x

Price-To-Earnings vs Fair Ratio: ABCL is expensive based on its Price-To-Earnings Ratio (14x) compared to the estimated Fair Price-To-Earnings Ratio (11.8x).


Share Price vs Fair Value

What is the Fair Price of ABCL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ABCL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ABCL's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: ABCL's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Discover undervalued companies

Future Growth

How is AbCellera Biologics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-52.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABCL's earnings are forecast to decline over the next 3 years (-52.3% per year).

Earnings vs Market: ABCL's earnings are forecast to decline over the next 3 years (-52.3% per year).

High Growth Earnings: ABCL's earnings are forecast to decline over the next 3 years.

Revenue vs Market: ABCL's revenue is expected to decline over the next 3 years (-38.9% per year).

High Growth Revenue: ABCL's revenue is forecast to decline over the next 3 years (-38.9% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ABCL's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has AbCellera Biologics performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


88.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ABCL has high quality earnings.

Growing Profit Margin: ABCL's current net profit margins (41.9%) are lower than last year (47.1%).


Past Earnings Growth Analysis

Earnings Trend: ABCL's earnings have grown significantly by 88.3% per year over the past 5 years.

Accelerating Growth: ABCL's earnings growth over the past year (0.8%) is below its 5-year average (88.3% per year).

Earnings vs Industry: ABCL earnings growth over the past year (0.8%) underperformed the Life Sciences industry 21%.


Return on Equity

High ROE: ABCL's Return on Equity (17%) is considered low.


Discover strong past performing companies

Financial Health

How is AbCellera Biologics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: ABCL's short term assets ($1.2B) exceed its short term liabilities ($213.4M).

Long Term Liabilities: ABCL's short term assets ($1.2B) exceed its long term liabilities ($171.4M).


Debt to Equity History and Analysis

Debt Level: ABCL is debt free.

Reducing Debt: ABCL had no debt 5 years ago.

Debt Coverage: ABCL has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ABCL has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is AbCellera Biologics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ABCL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABCL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ABCL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABCL's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ABCL has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Carl Hansen (46 yo)

9.58yrs

Tenure

US$9,116,252

Compensation

Dr. Carl L. G. Hansen, Ph.D. is a Co-Founder of AbCellera Biologics Inc. and has been its Chief Executive Officer and Director since November 2012 and serves as its Chairperson. Dr. Hansen serves as a Memb...


CEO Compensation Analysis

Compensation vs Market: Carl's total compensation ($USD9.12M) is above average for companies of similar size in the US market ($USD6.90M).

Compensation vs Earnings: Carl's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ABCL's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: ABCL's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ABCL insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5%.


Top Shareholders

Company Information

AbCellera Biologics Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: AbCellera Biologics Inc.
  • Ticker: ABCL
  • Exchange: NasdaqGS
  • Founded: 2012
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$2.877b
  • Shares outstanding: 284.54m
  • Website: https://www.abcellera.com

Number of Employees


Location

  • AbCellera Biologics Inc.
  • 2215 Yukon Street
  • Vancouver
  • British Columbia
  • V5Y 0A1
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/29 00:00
End of Day Share Price2022/06/29 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.